These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30891620)

  • 1. ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.
    Rosas J; Sánchez-Piedra C; Fernández-Castro M; Andreu JL; Martínez-Taboada V; Olivé A;
    Rheumatol Int; 2019 Jun; 39(6):991-999. PubMed ID: 30891620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
    Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
    Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 4. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
    Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
    Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.
    Heus A; Arends S; Van Nimwegen JF; Stel AJ; Nossent GD; Bootsma H
    Scand J Rheumatol; 2020 Jan; 49(1):38-46. PubMed ID: 31556344
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER).
    Torrente-Segarra V; Corominas H; Sánchez-Piedra C; Fernández-Castro M; Andreu JL; Martínez-Taboada VM; Olivé A; Rosas J; Sánchez-Alonso F;
    Clin Exp Rheumatol; 2017; 35 Suppl 105(3):28-34. PubMed ID: 28240585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    De Vita S; Gandolfo S; Zandonella Callegher S; Zabotti A; Quartuccio L
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):150-156. PubMed ID: 30156548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
    Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
    J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
    Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
    Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
    Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
    Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients.
    Retamozo S; Acar-Denizli N; Rasmussen A; Horváth IF; Baldini C; Priori R; Sandhya P; Hernandez-Molina G; Armagan B; Praprotnik S; Kvarnstrom M; Gerli R; Sebastian A; Solans R; Rischmueller M; Pasoto SG; Valim V; Nordmark G; Kruize A; Nakamura H; Hofauer B; Giacomelli R; Fernandes Moça Trevisani V; Devauchelle-Pensec V; Atzeni F; Gheita TA; Consani-Fernández S; Szántó A; Sivils K; Gattamelata A; Danda D; Kilic L; Bartoloni E; Bombardieri S; Sánchez-Guerrero J; Wahren-Herlenius M; Mariette X; Ramos-Casals M; Brito-Zerón P;
    Clin Exp Rheumatol; 2019; 37 Suppl 118(3):97-106. PubMed ID: 31464664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.